Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Androgen receptor pathway inhibitors
12 evidence topics · 15 sources
Enzalutamide: FDA-approved indications
Abiraterone acetate: FDA-approved indications
Apalutamide: FDA-approved indications
Darolutamide: FDA-approved indications
Guideline statements on sequencing androgen receptor pathway inhibitors
Randomized crossover trial of abiraterone and enzalutamide sequences
“Primary endpoints were time to second PSA progression and PSA response (≥30% decline from baseline) on second-line therapy, analysed by intention-to-treat in all randomly assigned patients and in patients who crossed over, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PSA responses to second-line therapy were seen in 26 (36%) of 73 patients for enzalutamide and three (4%) of 75 for abiraterone (χ2 p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Enzalutamide showed activity as a second-line novel androgen receptor pathway inhibitor, whereas abiraterone acetate did not, leading to a longer time to second PSA progression for the sequence of abiraterone followed by enzalutamide than with the opposite treatment sequence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Single-arm study of enzalutamide after abiraterone
“Multicentre, single-arm, open-label study, enrolled patients with progressing mCRPC after ≥24 wk of abiraterone acetate plus prednisone treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median radiographic progression-free survival was 8.1 mo (95% confidence interval: 6.1-8.3); median overall survival had not been reached.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Unconfirmed PSA response rate was 27% (48 of 181).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adding enzalutamide to abiraterone at PSA progression on enzalutamide: PLATO
“Median progression-free survival was 5.7 months in the combination group and 5.6 months in the control group (hazard ratio, 0.83; 95% CI, 0.61 to 1.12; P = .22).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PLATO also reported limited benefit with abiraterone after enzalutamide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, results from PLATO suggest that enzalutamide should not be continued in combination with abiraterone after PSA progression during enzalutamide monotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Second inhibitor after docetaxel and one inhibitor: CARD control arm
“The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling-targeted inhibitor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P = 0.008).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Change of inhibitor in taxane-naive disease: PSMAfore control arm
“Eligible patients were adults with PSMA-positive mCRPC who were candidates for a change of ARPI following one instance of disease progression on abiraterone, enzalutamide, darolutamide, or apalutamide as their most recent anticancer therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At third data cut-off after 334 rPFS events, the updated hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·49 (95% CI, 0·39–0·61); the median rPFS was 11·60 months (95% CI, 9·30–14·19) vs 5·59 months (4·21–5·95)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At third data cut-off, the proportion of patients with confirmed prostate-specific antigen (PSA) decline of at least 50% from baseline was higher with 177 Lu-PSMA-617 vs ARPI change (51% [95% CI, 43·8–57·5] vs 17% [12·6–22·9])” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the ARPI change group, the median duration of exposure was 6·52 months (IQR, 7·77); 100 patients received abiraterone and 132 patients received enzalutamide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote